Spero Therapeutics

Historical price data

Spero Therapeutics is a Boston-based biotech focused on rare diseases and antibiotic-resistant infections, leveraging a capital-efficient, partnership-driven model. Its defining achievement is the positive Phase 3 readout for tebipenem HBr, an oral carbapenem for complicated urinary tract infections, which could become the first oral drug in its class and offers a paradigm shift from IV to oral treatment. The company's strategy involves in-licensing and developing assets with clear differentiation, targeting areas with scarce therapeutic options. With a lean team and a history of strategic collaborations, Spero is poised to advance its lead candidate toward regulatory submission while exploring its pipeline.

Spero employs a strategic, partnership-driven development model focused on identifying and advancing novel therapeutic candidates with clear differentiation (e.g., oral bioavailability for IV-only drug classes) for high-unmet-need niches in rare diseases and multidrug-resistant infections.

Tebipenem HBr's primary competition is the current standard of IV antibiotics and hospitalization; its key differentiator is its oral formulation enabling site-of-care shift. In the broader landscape, it competes with other IV agents for resistant Gram-negative infections but will face limited direct oral competition. In NTM, SPR720 would compete against complex, toxic multidrug regimens and newer inhaled therapies.